Silexion Therapeutics Corp (SLXNW) Free cash flow 2023–2025
Silexion Therapeutics Corp (SLXNW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$10.8MFY2025 · since FY2023: -$4.5M → -$10.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$10.8M | -28.6% |
| FY2024 | -$8.4M | -85.4% |
| FY2023 | -$4.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SLXNW financial trends
SLXNW RevenueSLXNW Net incomeSLXNW Net marginSLXNW Gross profitSLXNW Gross marginSLXNW Operating incomeSLXNW Operating marginSLXNW Operating cash flowSLXNW Capital expendituresSLXNW Return on equitySLXNW Stock buybacksSLXNW Dividends paidSLXNW Total assetsSLXNW Total liabilitiesSLXNW Shareholders’ equitySLXNW overview →